Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30


Molecular characterization of breast cancer cell lines through multiple omic approaches.

Smith SE, Mellor P, Ward AK, Kendall S, McDonald M, Vizeacoumar FS, Vizeacoumar FJ, Napper S, Anderson DH.

Breast Cancer Res. 2017 Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0.


Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro.

Goyette S, Liang Y, Mafuvadze B, Cook MT, Munir M, Hyder SM.

Breast Cancer (Dove Med Press). 2017 May 19;9:347-357. doi: 10.2147/BCTT.S135371. eCollection 2017.


Phytosteroids beyond estrogens: Regulators of reproductive and endocrine function in natural products.

Dean M, Murphy BT, Burdette JE.

Mol Cell Endocrinol. 2017 Feb 15;442:98-105. doi: 10.1016/j.mce.2016.12.013. Epub 2016 Dec 13. Review.


Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.

Liang Y, Mafuvadze B, Aebi JD, Hyder SM.

Onco Targets Ther. 2016 May 30;9:3223-32. doi: 10.2147/OTT.S105725. eCollection 2016.


The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.

Flores VA, Taylor HS.

Endocrinol Metab Clin North Am. 2015 Sep;44(3):587-602. doi: 10.1016/j.ecl.2015.05.007. Epub 2015 Jun 23. Review.


Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts.

Cook MT, Liang Y, Besch-Williford C, Goyette S, Mafuvadze B, Hyder SM.

Springerplus. 2015 Aug 22;4:444. doi: 10.1186/s40064-015-1242-x. eCollection 2015.


Progesterone receptor modulates ERĪ± action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum in: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A].


Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, Polo ML, Gorostiaga MA, Jacobsen B, Molinolo A, Novaro V, Lanari C.

Int J Cancer. 2015 Jun 1;136(11):2680-92. doi: 10.1002/ijc.29304. Epub 2014 Nov 12.


The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Sequeira G, Vanzulli SI, Rojas P, Lamb C, Colombo L, May M, Molinolo A, Lanari C.

Oncotarget. 2014 May 30;5(10):3246-60.


The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.

Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM.

Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24.


Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H, Wang C, Wang X, Yang G, Cai X, Falck JR, Yang J.

Toxicol Appl Pharmacol. 2012 Oct 1;264(1):73-83. doi: 10.1016/j.taap.2012.07.019. Epub 2012 Jul 25.


Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.

Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, Lange CA.

Breast Cancer Res. 2012 Jun 14;14(3):R95.


Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV.

Breast Cancer Res. 2012 May 14;14(3):R77.


Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.

Periyasamy-Thandavan S, Takhar S, Singer A, Dohn MR, Jackson WH, Welborn AE, LeRoith D, Marrero M, Thangaraju M, Huang S, Schoenlein PV.

Breast Cancer Res. 2012 Mar 19;14(2):R52.


Changing concepts: Menopausal hormone therapy and breast cancer.

Chlebowski RT, Anderson GL.

J Natl Cancer Inst. 2012 Apr 4;104(7):517-27. doi: 10.1093/jnci/djs014. Epub 2012 Mar 16. Review.


The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.

Yuan H, Upadhyay G, Lu J, Kopelovich L, Glazer RI.

Cancer Prev Res (Phila). 2012 May;5(5):754-64. doi: 10.1158/1940-6207.CAPR-11-0526. Epub 2012 Mar 16.


Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells.

Yin P, Roqueiro D, Huang L, Owen JK, Xie A, Navarro A, Monsivais D, Coon JS 5th, Kim JJ, Dai Y, Bulun SE.

PLoS One. 2012;7(1):e29021. doi: 10.1371/journal.pone.0029021. Epub 2012 Jan 17.


Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence.

Atif F, Sayeed I, Yousuf S, Ishrat T, Hua F, Wang J, Brat DJ, Stein DG.

Mol Med. 2011 Sep-Oct;17(9-10):1084-94. doi: 10.2119/molmed.2010.00255. Epub 2011 Jun 17.

Supplemental Content

Support Center